03 Dec 2012
(MENAFN) Merck Serono’s CEO, Stefan Oschmann, said that the company, a subsidiary of Germany’s Merck KgaA, has signed a partnership agreement with UAE’s Neopharma, reported Emirates News Agency (WAM).
Neopharma, chaired by Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Higher Education and Scientific Research, would start producing Merck branded medication in the UAE for distribution across the Middle East.
Oschmann said that the deal means that Merck Serono will be the first multinational pharmaceutical firm to work with a local producer to supply the region with vital pharmaceutical products through export out of the UAE manufacturing base.
At the start, Neopharma will begin producing two Merck Serono products, the first, Euthyrox, a hormone therapy requiring a very stringent sterile environment for production and packaging, and the second one is Glucophage, a standard oral treatment for people suffering from type 2 diabetes that helps control blood sugar levels.
Production of the two medications will start next year.
It is worth noting that around 827,000 people between the ages of 20 and 79 are diagnosed with diabetes in the UAE.
28 Jul 2025
BBK discloses its financial results for the half year ended 30th June 2025
20 Jul 2025
CBB approves the transfer of the retail banking operations of HSBC Bank Middle East, Bahrain Branch to BBK
08 Jul 2025
BBK proudly launches the third edition of “Grow” and welcomes 20 Bahraini graduates
03 Jul 2025
BBK hosts executive leadership session on digital assets in collaboration with Rain
02 Jul 2025
BBK launches the largest-ever Al Hayrat Prizes, offering BD 5 million to over 2,000 winners
16 Jun 2025
BBK and CrediMax Offer Exclusive 20% Discount on Turkish Airlines Flights for Cardholders
25 May 2025
BBK strengthens commitment to sports development through strategic partnership with Bahrain Basketball Association
This website uses cookies to ensure you get the best experience and by clicking “I Accept” below, you consent to the use of cookies. Learn more